Rockwell Medical Submits Supplemental Data to FDA for IND Application for Phase 2 FPC Home Infusion Trial

WIXOM, Mich., May 12, 2022 /PRNewswire/ — Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that it provided the U.S. Food and Drug Administration (FDA) with the…

About the Author

has written 21729 stories on this site.

Copyright © 2010-2019 strategicbusinessnews.com